Looking Beyond Weight Loss In The Obesity Pandemic: What's Next?
The recent success of GLP-1 receptor agonist drugs in achieving weight loss has thrust obesity into the spotlight as a chronic disease requiring comprehensive management.
Projections suggest that by 2035, more than half of the global population will be affected by obesity, imposing significant economic and healthcare burdens. Clinical trials have shown that GLP-1 drugs can lead to an average weight loss of 15%, surpassing traditional lifestyle interventions and competing with surgical options. This success has garnered substantial attention in social and mainstream media, highlighting its societal impact.
Despite these promising results, the long-term benefits of GLP-1 treatments for obesity are still debated. Concerns extend beyond common side effects like nausea and diarrhea to potential issues such as muscle loss and the sustainability of weight maintenance. If weight loss predominantly involves muscle mass, patients may face challenges in physical function, especially if treatment discontinuation leads to fat regain instead. Patients are increasingly aware of these risks and are adopting proactive lifestyle changes, including physical activity to preserve muscle mass and support lasting weight management.
However, clinical trials often lack robust data on physical activity. Wearable digital health technology (DHT) offers a promising solution by providing continuous, objective insights into physical activity levels. This white paper examines the current landscape of obesity management, emphasizing the importance of holistic approaches that go beyond mere weight loss.
Get unlimited access to:
Enter your credentials below to log in. Not yet a member of Clinical Leader? Subscribe today.